KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EBT (2016 - 2025)

Acadia Pharmaceuticals has reported EBT over the past 16 years, most recently at $26.3 million for Q4 2025.

  • Quarterly results put EBT at $26.3 million for Q4 2025, down 83.66% from a year ago — trailing twelve months through Dec 2025 was $138.9 million (down 46.17% YoY), and the annual figure for FY2025 was $138.9 million, down 46.18%.
  • EBT for Q4 2025 was $26.3 million at Acadia Pharmaceuticals, down from $44.6 million in the prior quarter.
  • Over the last five years, EBT for ACAD hit a ceiling of $161.1 million in Q4 2024 and a floor of -$112.6 million in Q1 2022.
  • Median EBT over the past 5 years was -$4.2 million (2021), compared with a mean of -$1.8 million.
  • Biggest five-year swings in EBT: tumbled 97.4% in 2023 and later skyrocketed 490.19% in 2024.
  • Acadia Pharmaceuticals' EBT stood at -$42.9 million in 2021, then increased by 4.8% to -$40.8 million in 2022, then surged by 197.11% to $39.7 million in 2023, then surged by 306.1% to $161.1 million in 2024, then tumbled by 83.66% to $26.3 million in 2025.
  • The last three reported values for EBT were $26.3 million (Q4 2025), $44.6 million (Q3 2025), and $40.2 million (Q2 2025) per Business Quant data.